Clinical trial · Observational
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT (EPithelial ImmunoSPOT) and CellSearch Techniques
NCT01558349CI-TRIAL-00097487completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to compare results for the detection of circulating melanoma cells (CMC) using CellSearch versus EPISPOT (EPithelial ImmunoSPOT) techniques between a group of patients with metastatic melanoma and a group of hospitalized control patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Hospitalized controls
- description
- Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
- label
- Metastatic melanoma
- description
- This cohort includes patients with metastatic melanoma.
Primary outcomes (1)
- measure
- Presence/absence of at least 2 CMCs per ml blood, both techniques
- timeFrame
- Day 1 at 8 am
- description
- Presence/absence of at least 2 CMCs per ml blood, using both the Epispot and the CellSearch techniques
Secondary outcomes (6)
- measure
- CMCs per ml blood, Epispot
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available, within the hours of his/her normally scheduled medical care, for blood sampling at 8 am and 4 pm on the same day. Inclusion Criteria for patients: * Stage 4 melanoma, without other associated neoplasms Inclusion Criteria for controls: * Patient without cancer, nor history of cancer Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The patient has a contra-indication for a treatment used in this study Exclusion criteria for patients: * Stage 1 to 3 melanoma, or other types of cancer Exclusion criteria for controls: * History of cancer
References
Publications (1)
- RESULTCayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, Perriard F, Daures JP, Meunier L, Alix-Panabieres C. S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells. Cells. 2019 Jul 20;8(7):755. doi: 10.3390/cells8070755. PMID 31330795